MAPT and Alzheimer disease: Note: Although no patients in the ApoE4(+) group were diagnosed with DS-AD at the time of plasma collection, four ApoE4(+) patients with elevated p-tau levels were confirmed to develop DS-AD within the next 2–3 years.